Dual Functionalized Liposomes for Selective Delivery of Poorly Soluble Drugs to Inflamed Brain Regions.
blood–brain barrier
glibenclamide
lipopeptides
matrix metalloproteinases
neuroinflammation
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 Nov 2022
07 Nov 2022
Historique:
received:
23
09
2022
revised:
28
10
2022
accepted:
01
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Dual functionalized liposomes were developed to cross the blood−brain barrier (BBB) and to release their cargo in a pathological matrix metalloproteinase (MMP)-rich microenvironment. Liposomes were surface-functionalized with a modified peptide deriving from the receptor-binding domain of apolipoprotein E (mApoE), known to promote cargo delivery to the brain across the BBB in vitro and in vivo; and with an MMP-sensitive moiety for an MMP-triggered drug release. Different MMP-sensitive peptides were functionalized at both ends with hydrophobic stearate tails to yield MMP-sensitive lipopeptides (MSLPs), which were assembled into mApoE liposomes. The resulting bi-functional liposomes (i) displayed a < 180 nm diameter with a negative ζ-potential; (ii) were able to cross an in vitro BBB model with an endothelial permeability of 3 ± 1 × 10−5 cm/min; (iii) when exposed to functional MMP2 or 9, efficiently released an encapsulated fluorescein dye; (iv) showed high biocompatibility when tested in neuronal cultures; and (v) when loaded with glibenclamide, a drug candidate with poor aqueous solubility, reduced the release of proinflammatory cytokines from activated microglial cells.
Identifiants
pubmed: 36365220
pii: pharmaceutics14112402
doi: 10.3390/pharmaceutics14112402
pmc: PMC9698607
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Regionale per la Ricerca Biomedica (Regione Lombardia) CP2_16/2018
ID : CP2_16/2018
Références
J Med Chem. 2009 Mar 12;52(5):1310-6
pubmed: 19199479
J Control Release. 2020 Apr 10;320:142-158
pubmed: 31978442
Neurocrit Care. 2018 Aug;29(1):119-127
pubmed: 29150777
Bioinformatics. 2011 Jun 15;27(12):1630-6
pubmed: 21505036
Pharm Res. 2021 Jun;38(6):1081-1092
pubmed: 34002324
Neurosci Lett. 2020 Jan 23;718:134729
pubmed: 31899311
J Mater Chem B. 2015 Jun 21;3(23):4723-4734
pubmed: 26085928
J Control Release. 2017 Jul 28;258:121-129
pubmed: 28501671
ACS Nano. 2012 Apr 24;6(4):3491-8
pubmed: 22409425
PLoS One. 2020 Oct 12;15(10):e0240234
pubmed: 33045007
Eur J Pharm Biopharm. 2018 Jun;127:387-397
pubmed: 29581043
Int J Pharm. 2016 Apr 11;502(1-2):161-9
pubmed: 26921515
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
Pharmaceuticals (Basel). 2013 Oct 11;6(10):1287-303
pubmed: 24275850
Cell. 2018 May 17;173(5):1073-1081
pubmed: 29775591
Neoplasia. 2013 May;15(5):535-43
pubmed: 23633925
J Control Release. 2014 Dec 28;196:113-21
pubmed: 25312543
Drug Discov Today. 2021 Aug;26(8):1794-1824
pubmed: 34058372
J Neurosci. 2014 Oct 15;34(42):14022-31
pubmed: 25319699
Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64
pubmed: 23212117
ACS Nano. 2017 Sep 26;11(9):8668-8678
pubmed: 28806504
J Biotechnol. 2011 Dec 20;156(4):341-6
pubmed: 21763360
Int J Pharm. 2021 Jan 5;592:120051
pubmed: 33161039
J Neurosci. 2003 Sep 17;23(24):8568-77
pubmed: 13679426
J Mol Biol. 1999 Jun 4;289(2):413-28
pubmed: 10366514
PLoS One. 2015 Jul 30;10(7):e0134476
pubmed: 26225433
J Nanobiotechnology. 2019 Apr 3;17(1):49
pubmed: 30943991
J Control Release. 2006 Apr 10;111(3):333-42
pubmed: 16488046
Theranostics. 2018 Feb 5;8(6):1481-1493
pubmed: 29556336
Front Bioeng Biotechnol. 2019 Dec 12;7:403
pubmed: 31921808
Langmuir. 2005 Jun 7;21(12):5290-7
pubmed: 15924452
Neuropharmacology. 2017 Jul 15;121:1-11
pubmed: 28412320
Front Neurosci. 2019 May 16;13:419
pubmed: 31156358
Drug Deliv Transl Res. 2020 Aug;10(4):862-877
pubmed: 32103449
Int J Mol Sci. 2022 Apr 09;23(8):
pubmed: 35456971
Neurooncol Adv. 2021 Jun 18;3(1):vdab076
pubmed: 34377986
J Cereb Blood Flow Metab. 2009 Feb;29(2):317-30
pubmed: 18854840
Int J Mol Sci. 2020 Jan 09;21(2):
pubmed: 31936452
Biomaterials. 2017 Mar;121:130-143
pubmed: 28088075
Front Neurosci. 2021 Sep 24;15:742065
pubmed: 34630027
Cancers (Basel). 2022 Jun 16;14(12):
pubmed: 35740641
Expert Rev Anticancer Ther. 2016 May;16(5):485-92
pubmed: 27043737
Molecules. 2022 Feb 17;27(4):
pubmed: 35209162
Pharm Res. 2006 Jul;23(7):1417-50
pubmed: 16779701
Colloids Surf B Biointerfaces. 2008 Feb 15;61(2):270-6
pubmed: 17928204
J Nanobiotechnology. 2019 Nov 11;17(1):115
pubmed: 31711496
J Neuroinflammation. 2015 Nov 18;12:210
pubmed: 26581714
Nanomedicine. 2016 Jan;12(1):43-52
pubmed: 26410276
Brain Behav Immun. 2015 Mar;45:263-76
pubmed: 25499583
J Biol Chem. 2002 Feb 8;277(6):4485-91
pubmed: 11694539
Stroke. 2022 May;53(5):1473-1486
pubmed: 35387495
Nanomedicine. 2011 Oct;7(5):551-9
pubmed: 21658472
Pharm Res. 1994 Jan;11(1):111-6
pubmed: 8140040
Diabetes Res Clin Pract. 2000 Aug;49(2-3):93-9
pubmed: 10963819
Stroke. 1999 Sep;30(9):1942-7; discussion 1947-8
pubmed: 10471448
Biomater Sci. 2021 Mar 21;9(6):2032-2042
pubmed: 33544109
Nanomedicine. 2014 Oct;10(7):1583-90
pubmed: 24333591